Alnylam Pharmaceuticals, Inc.
ALNYAlnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Drugs in Pipeline
20
Phase 3 Programs
8
Upcoming Catalysts
2
Next Catalyst
Jul 30, 2026
6wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Amvuttra
Vutrisiran
hATTR Amyloidosis
Lumasiran
PH1
Nucresiran
Transthyretin Amyloidosis With Cardiomyopathy
patisiran (ALN-TTR02)
TTR-mediated Amyloidosis
Vutrisiran
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Givosiran
Acute Hepatic Porphyria
Patisiran
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Zilebesiran
Hypertension
Revusiran (ALN-TTRSC)
TTR-mediated Amyloidosis
ALN-RSV01
Respiratory Syncytial Virus Infections
ALN-AGT01
Hypertension
ALN-6400
Hereditary Hemorrhagic Telangiectasia
Revusiran
Transthyretin (TTR)-Mediated Amyloidosis
ALN-APP
Alzheimer Disease
ALN-2232
Obesity
ALN-AGT01 RVR
Hypertension
ALN-CC5
Paroxysmal Nocturnal Hemoglobinuria (PNH)
ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
TTR-mediated Amyloidosis
ALN-4324
Obese or Overweight Healthy Volunteers
ALN-TTRSC (revusiran) for subcutaneous administration
TTR-mediated Amyloidosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Amvuttra Vutrisiran | Approved | hATTR Amyloidosis | OrphanFast Track | Patent 2036 |
Lumasiran | Phase 3 | PH1 | - | - |
Nucresiran | Phase 3 | Transthyretin Amyloidosis With Cardiomyopathy | - | - |
patisiran (ALN-TTR02) | Phase 3 | TTR-mediated Amyloidosis | - | - |
Vutrisiran | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | - | - |
Givosiran | Phase 3 | Acute Hepatic Porphyria | - | - |
Patisiran | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | - | - |
Zilebesiran | Phase 3 | Hypertension | - | - |
Revusiran (ALN-TTRSC) | Phase 3 | TTR-mediated Amyloidosis | - | - |
ALN-RSV01 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
ALN-AGT01 | Phase 2 | Hypertension | - | - |
ALN-6400 | Phase 2 | Hereditary Hemorrhagic Telangiectasia | - | - |
Revusiran | Phase 2 | Transthyretin (TTR)-Mediated Amyloidosis | - | - |
ALN-APP | Phase 2 | Alzheimer Disease | OrphanFast TrackBreakthrough | - |
ALN-2232 | Phase 2 | Obesity | - | - |
ALN-AGT01 RVR | Phase 2 | Hypertension | - | - |
ALN-CC5 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
ALN-TTR02 (patisiran) administered by intravenous (IV) infusion | Phase 2 | TTR-mediated Amyloidosis | - | - |
ALN-4324 | Phase 2 | Obese or Overweight Healthy Volunteers | - | - |
ALN-TTRSC (revusiran) for subcutaneous administration | Phase 2 | TTR-mediated Amyloidosis | - | - |
Hypertension
1 drug in this indication
Alzheimer Disease
1 drug in this indication
hATTR Amyloidosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)